v3.26.1
Segment Reporting - Summary of Financial Information for Segment (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]      
Collaboration revenue $ 0 $ 0 $ 7,000
External costs by program      
Research and development 33,756 65,742 85,697
General and administrative 18,514 23,393 26,540
Total operating expenses 59,107 90,605 118,424
Loss from operations (59,107) (90,605) (111,424)
Interest income 4,444 8,462 11,104
Net loss (56,033) (83,736) (101,870)
Reportable Segment      
Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]      
Collaboration revenue 0 0 7,000
Internal costs      
Total salary / benefits 21,800 21,228 30,105
External costs by program      
General and administrative 9,523 10,888 13,663
Other segment items 11,057 15,608 22,111
Total operating expenses 59,107 90,605 118,424
Loss from operations (59,107) (90,605) (111,424)
Interest income 4,444 8,462 11,104
Other expenses (1,370) (1,593) (1,550)
Net loss (56,033) (83,736) (101,870)
Reportable Segment | Zetomipzomib      
External costs by program      
Research and development 15,855 36,652 40,513
Reportable Segment | KZR-261      
External costs by program      
Research and development 839 5,940 6,428
Reportable Segment | Other protein secretion discovery programs      
External costs by program      
Research and development $ 33 $ 289 $ 5,604